XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in thousands)
Revenue$10,739 $1,726 $12,503 $3,258 
Less:
Research and development employee expense, lab supplies and overhead2,297 6,908 6,733 14,008 
Imdusiran IM-PROVE I, II & III clinical trials expense1,405 4,010 3,789 9,399 
AB-101-001 Phase 1a/1b clinical trial expense1,738 3,186 3,637 5,996 
Other early research and development programs expense58 1,447 298 1,551 
General and administrative expense3,328 7,547 9,160 12,859 
Restructuring expense165 — 12,538 — 
Other segment expense (1)
267 253 590 490 
Add:
Interest income1,042 1,829 2,239 3,374 
Segment net income (loss)$2,523 $(19,796)$(22,003)$(37,671)
Adjustments and reconciling items— — — — 
Consolidated net income (loss)$2,523 $(19,796)$(22,003)$(37,671)

(1) Other segment expense includes the change in the fair value of contingent consideration, non-cash interest expenses and foreign currency exchange gains and losses.